<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Drug-development on Chatomics</title>
    <link>https://divingintogeneticsandgenomics.com/tags/drug-development/</link>
    <description>Recent content in Drug-development on Chatomics</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2018 Ming &#39;Tommy&#39; Tang</copyright>
    <lastBuildDate>Fri, 24 Apr 2026 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="https://divingintogeneticsandgenomics.com/tags/drug-development/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Has AI Changed the Course of Drug Development? Three Years Later</title>
      <link>https://divingintogeneticsandgenomics.com/post/has-ai-changed-drug-development-3-years-later/</link>
      <pubDate>Fri, 24 Apr 2026 00:00:00 +0000</pubDate>
      
      <guid>https://divingintogeneticsandgenomics.com/post/has-ai-changed-drug-development-3-years-later/</guid>
      <description>Almost three years ago I wrote Has AI Changed the Course of Drug Development?. The post was cautiously skeptical. AlphaFold was the headline. BenevolentAI had just flopped a Phase 2a in atopic dermatitis. Verge Genomics&amp;rsquo; VRG50635 was about to enter the clinic. I argued that data quality was the real bottleneck, not algorithms.
Time to revisit that.
I now lead epigenomics bioinformatics at AstraZeneca and I use Claude Code daily.</description>
    </item>
    
  </channel>
</rss>